Article

Maternal antibodies to pneumolysin but not to pneumococcal surface protein A delay early pneumococcal carriage in high-risk Papua New Guinean infants.

Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.
Clinical and vaccine Immunology: CVI (Impact Factor: 2.37). 09/2009; 16(11):1633-8. DOI: 10.1128/CVI.00247-09
Source: PubMed

ABSTRACT Immunization of pregnant women can be an efficient strategy to induce early protection in infants in developing countries. Pneumococcal protein-based vaccines may have the capacity to induce pneumococcal serotype-independent protection. To understand the potential of maternal pneumococcal protein-specific antibodies in infants in high-risk areas, we studied the placental transfer of naturally acquired antibodies to pneumolysin (Ply) and pneumococcal surface protein A family 1 and 2 (PspA1 and PspA2) in relation to onset of pneumococcal nasopharyngeal carriage in infants in Papua New Guinea (PNG). In this study, 76% of the infants carried Streptococcus pneumoniae in the upper respiratory tract within the first month of life, at a median age of 19 days. Maternal and cord blood antibody titers to Ply (rho = 0.824, P < 0.001), PspA1 (rho = 0.746, P < 0.001), and PspA2 (rho = 0.631, P < 0.001) were strongly correlated. Maternal pneumococcal carriage (hazard ratio [HR], 2.60; 95% confidence interval [CI], 1.25 to 5.39) and younger maternal age (HR, 0.74; 95% CI, 0.54 to 1.00) were independent risk factors for early carriage, while higher cord Ply-specific antibody titers predicted a significantly delayed onset (HR, 0.71; 95% CI, 0.52 to 1.00) and cord PspA1-specific antibodies a significantly younger onset of carriage in PNG infants (HR, 1.57; 95% CI, 1.03 to 2.40). Maternal vaccination with a pneumococcal protein-based vaccine should be considered as a strategy to protect high-risk infants against pneumococcal disease by reducing carriage risks in both mothers and infants.

Download full-text

Full-text

Available from: William Pomat, Jun 30, 2015
0 Followers
 · 
176 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Utilizing optimization programs may facilitate the task of the MV distribution network planner. Suitable algorithms and programs have been developed for medium term planning of large distribution networks with several hundred load points. An important aspect of power system planning is to achieve a predetermined standard of service reliability. In this paper models, algorithms and computational techniques for quantitative network reliability assessment are presented, and some examples of application are illustrated
    Transmission and Distribution Construction and Live Line Maintenance, 1995. ESMO-95 Proceedings., Seventh International Conference on; 01/1995
  • [Show abstract] [Hide abstract]
    ABSTRACT: The standard treatment of elderly head and neck patients is controversial. The goal of this study was to evaluate the relationship between co-morbidity and complications in elderly laryngeal cancer patients treated with different modalities. Retrospective analysis of patients 75 years old and older with laryngeal cancer (n=139) and patients 65 years old and younger as a reference control group (n=289) diagnosed in our department between 1997 and 2007 has been performed. Pretreatment co-morbidity (ACE-27), treatment-related complications and one- and six-month death rates have been analyzed. Co-morbidity rate was more pronounced in the elderly group, but did not result in more complications. Correlation has been found between co-morbidity and complication in the whole patients group, but not in the elderly group. By multivariate analysis, in all age groups radiation therapy (vs. total laryngectomy) and tumor stage were predictors of complications but co-morbidity and age were not. According to our study there is no reason to treat elderly laryngeal cancer patients differently. The weaker relation between co-morbidity and complications emphasizes the importance of careful pre-treatment evaluation in elderly.
    Oral Oncology 01/2011; 47(1):56-61. DOI:10.1016/j.oraloncology.2010.10.016 · 3.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recognition of the high burden of disease in early life and advances in the understanding of neonatal immunology have resulted in renewed interest in maternal and neonatal vaccination. This article reviews existing information and recent advances in neonatal human immunization. Recent findings have demonstrated the neonatal immune system not to be immature but rather specifically adapted for early postnatal life. This includes the preferential induction of memory B cell rather than antibody-secreting plasma cells and polarization of neonatal T-cell responses away from potentially deleterious T-helper type 1 cytokines. Recent neonatal acellular pertussis and pneumococcal conjugate vaccine trials have proven that a birth dose of acellular pertussis and/or pneumococcal vaccine, in limited samples sizes, are well tolerated and immunogenic; however they have identified vaccine interference as a critical issue to address. Neonatal immunization may be a well tolerated and effective preventive strategy against early life pathogens. Research to better understand how neonatal vaccine responses are elicited and to identify optimal early life adjuvants and formulations may broaden neonatally vaccine-preventable diseases to pertussis, rotavirus and possibly influenza, further reducing disease burden in this vulnerable group. Hurdles to neonatal vaccination include safety concerns, both immunological and clinical, demonstration of vaccine efficacy and public acceptance.
    Current Opinion in Infectious Diseases 03/2011; 24(3):190-5. DOI:10.1097/QCO.0b013e328345d563 · 5.03 Impact Factor